Welcome to our dedicated page for Align Technology SEC filings (Ticker: ALGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Align Technology, Inc. (NASDAQ: ALGN) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a global medical device manufacturer focused on the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software, Align uses its SEC filings to report financial performance, governance changes, and other material events.
Investors can use this page to review current reports on Form 8-K, which in the provided examples include announcements of quarterly financial results and updates on executive and board changes. These filings often reference detailed press releases that discuss revenues, clear aligner case volumes, imaging systems and CAD/CAM services revenues, operating margins, restructuring charges, stock repurchases, and business outlook.
In addition to 8-Ks, users can expect to find annual reports on Form 10-K and quarterly reports on Form 10-Q (when available), which typically contain audited or reviewed financial statements, segment information, risk factors, and management’s discussion and analysis. For a company like Align in the medical device and digital dentistry space, these periodic reports are key sources for understanding trends in clear aligner volumes, adoption of iTero scanners and exocad software, and regional performance.
Stock Titan enhances the filings view with AI-powered summaries that explain complex sections of lengthy documents, helping users quickly identify items such as restructuring disclosures, research and development discussion, or references to intellectual property and legal proceedings. The page also surfaces insider transaction filings on Form 4 when available, allowing users to track reported purchases or sales of ALGN shares by directors and officers. Together, these tools help investors and researchers navigate Align Technology’s regulatory history and ongoing reporting obligations more efficiently.
Align Technology (ALGN) Q2 2025 10-Q highlights:
- Revenue: $1.01 bn, -1.6% YoY; Clear Aligner -3.3%, Systems & Services +5.6%.
- Margin: Gross margin 70.0% (70.2% LY); operating margin 16.1% vs 14.3% on lower legal costs.
- Earnings: Net income $124.6 m (+29%), diluted EPS $1.72 (+34%). Six-month EPS $2.98 (+11%).
- Cash & Liquidity: Cash & equivalents $901 m (-14% YTD); no debt; operating cash flow $181 m (-4%).
- Capital return: Completed $1 bn Jan-23 buyback; repurchased 1.34 m shares for $225 m in H1; new $1 bn Apr-25 program with $200 m OMR slated for H2.
- Share count: 72.5 m outstanding (-3.5% YoY).
- Legal/one-offs: Recorded $4.2 m additional accrual toward $31.75 m Section-1 antitrust settlement (prelim approval 5/28/25); VAT dispute with UK HMRC refunded ~$100 m but subject to appeal.
- Segment profit: Clear Aligner op-profit $267 m (-11%); Systems & Services $86 m (+21%).
- Balance sheet: Inventories $243.8 m (-4% YTD); goodwill now $491 m after Cubicure acquisition.
- Tax: Effective rate 28.2% vs 32.9%.
Key takeaways: Despite modest top-line contraction, disciplined expense control, share buybacks and favorable other income drove double-digit EPS growth. Cash burn and continuing legal/tax uncertainties temper outlook, but new $1 bn authorization reinforces management’s confidence.